CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Jazz Pharmaceuticals plc - JAZZ CFD

132.37
0.55%
Market Trading Hours* (UTC) Open now
Closes on Monday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.23
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Jazz Pharmaceuticals PLC ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 131.66
Open* 130.76
1-Year Change* 2.49%
Day's Range* 130.76 - 132.93
52 wk Range 120.64-160.96
Average Volume (10 days) 518.32K
Average Volume (3 months) 11.14M
Market Cap 8.57B
P/E Ratio -100.00K
Shares Outstanding 63.13M
Revenue 3.76B
EPS -1.77
Dividend (Yield %) N/A
Beta 0.71
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 22, 2023 131.66 -0.21 -0.16% 131.87 133.45 130.81
Sep 21, 2023 132.55 0.03 0.02% 132.52 133.22 131.51
Sep 20, 2023 133.14 2.42 1.85% 130.72 133.95 130.72
Sep 19, 2023 131.27 0.21 0.16% 131.06 132.68 130.68
Sep 18, 2023 132.24 0.52 0.39% 131.72 132.87 131.43
Sep 15, 2023 131.95 -1.00 -0.75% 132.95 133.85 131.63
Sep 14, 2023 133.65 0.10 0.07% 133.55 135.25 133.08
Sep 13, 2023 133.99 0.80 0.60% 133.19 135.40 133.01
Sep 12, 2023 135.57 0.53 0.39% 135.04 136.78 134.50
Sep 11, 2023 136.31 -0.17 -0.12% 136.48 137.44 135.09
Sep 8, 2023 136.27 1.32 0.98% 134.95 136.96 134.95
Sep 7, 2023 135.66 0.19 0.14% 135.47 136.72 135.21
Sep 6, 2023 136.45 -2.07 -1.49% 138.52 139.02 135.91
Sep 5, 2023 138.75 -3.19 -2.25% 141.94 142.46 138.49
Sep 1, 2023 143.65 0.34 0.24% 143.31 144.37 142.72
Aug 31, 2023 143.21 -0.33 -0.23% 143.54 146.35 142.72
Aug 30, 2023 145.19 2.71 1.90% 142.48 145.56 142.47
Aug 29, 2023 143.60 2.28 1.61% 141.32 143.72 140.97
Aug 28, 2023 142.00 0.95 0.67% 141.05 142.41 140.84
Aug 25, 2023 141.16 3.76 2.74% 137.40 141.66 137.40

Jazz Pharmaceuticals plc Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

21:05

Country

IE

Event

Q3 2023 Jazz Pharmaceuticals PLC Earnings Release
Q3 2023 Jazz Pharmaceuticals PLC Earnings Release

Forecast

-

Previous

-
Monday, February 26, 2024

Time (UTC)

21:05

Country

IE

Event

Q4 2023 Jazz Pharmaceuticals PLC Earnings Release
Q4 2023 Jazz Pharmaceuticals PLC Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3659.37 3094.24 2363.57 2161.76 1890.92
Revenue 3659.37 3094.24 2363.57 2161.76 1890.92
Cost of Revenue, Total 540.517 440.76 148.917 127.93 121.544
Gross Profit 3118.86 2653.48 2214.65 2033.83 1769.38
Total Operating Expense 3724.9 2923.96 1990.59 1629.39 1277.51
Selling/General/Admin. Expenses, Total 1376.17 1222.68 854.233 736.942 683.53
Research & Development 1034.6 505.748 586.625 409.701 226.616
Depreciation / Amortization 599.169 525.769 259.58 354.814 201.498
Unusual Expense (Income) 174.448 229 141.239 0 44.321
Operating Income -65.528 170.278 372.973 532.374 613.413
Interest Income (Expense), Net Non-Operating -307.256 -283.116 -97.878 -78.072 -86.153
Net Income Before Taxes -372.784 -112.838 275.095 454.302 527.26
Net Income After Taxes -214.139 -328.954 241.578 527.456 447.091
Minority Interest
Net Income Before Extra. Items -224.06 -329.668 238.616 523.367 447.091
Net Income -224.06 -329.668 238.616 523.367 447.098
Income Available to Common Excl. Extra. Items -224.06 -329.668 238.616 523.367 447.091
Income Available to Common Incl. Extra. Items -224.06 -329.668 238.616 523.367 447.098
Dilution Adjustment 0
Diluted Net Income -224.06 -329.668 238.616 523.367 447.098
Diluted Weighted Average Shares 62.539 59.694 56.517 57.55 61.221
Diluted EPS Excluding Extraordinary Items -3.58272 -5.52263 4.22202 9.09413 7.30289
Diluted Normalized EPS -1.7696 -3.02908 6.4166 9.09413 7.91677
Total Extraordinary Items 0 0.0075
Equity In Affiliates -9.921 -0.714 -2.962 -4.089
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 957.317 892.812 972.123 940.652 932.878
Revenue 957.317 892.812 972.123 940.652 932.878
Cost of Revenue, Total 97.537 128.644 167.364 133.661 124.208
Gross Profit 859.78 764.168 804.759 806.991 808.67
Total Operating Expense 799.681 766.757 1235.51 915.889 847.332
Selling/General/Admin. Expenses, Total 340.844 297.917 383.203 317.678 325.673
Research & Development 209.238 190.41 547.555 148.87 208.195
Depreciation / Amortization 152.062 149.786 137.387 141.232 148.456
Unusual Expense (Income) 0 174.448 40.8
Operating Income 157.636 126.055 -263.386 24.763 85.546
Interest Income (Expense), Net Non-Operating -75.852 -70.954 -76.607 -84.893 -64.532
Net Income Before Taxes 81.784 55.101 -339.993 -60.13 21.014
Net Income After Taxes 106.107 70.425 -239.951 -17.103 37.126
Equity In Affiliates -1.669 -1.005 -0.773 -2.545 -2.461
Net Income Before Extra. Items 104.438 69.42 -240.724 -19.648 34.665
Net Income 104.438 69.42 -240.724 -19.648 34.665
Income Available to Common Excl. Extra. Items 104.438 69.42 -240.724 -19.648 34.665
Income Available to Common Incl. Extra. Items 104.438 69.42 -240.724 -19.648 34.665
Diluted Net Income 104.438 69.42 -240.724 -19.648 34.665
Diluted Weighted Average Shares 73.54 73.771 63.061 62.785 63.431
Diluted EPS Excluding Extraordinary Items 1.42015 0.94102 -3.81732 -0.31294 0.5465
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 1.42015 0.94102 -3.81732 1.49308 0.96459
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2606.14 2611.33 2839.57 1630.27 1234.01
Cash and Short Term Investments 881.482 591.448 2132.77 1077.34 824.622
Cash & Equivalents 517.464
Short Term Investments 30 80.701 1615.65 744.172 609.016
Total Receivables, Net 742.628 563.36 396.49 355.987 263.838
Accounts Receivable - Trade, Net 651.493 563.36 396.49 355.987 263.838
Total Inventory 714.061 1072.72 95.396 78.608 52.956
Prepaid Expenses 91.912 131.413 62.422 39.434 25.017
Other Current Assets, Total 176.057 252.392 152.491 78.895 67.572
Total Assets 10835.3 12298.6 6535.9 5538.9 5203.49
Property/Plant/Equipment, Total - Net 301.376 343.423 257.104 270.891 200.358
Property/Plant/Equipment, Total - Gross 409.023 428.794 324.692 326.148 249.966
Accumulated Depreciation, Total -107.647 -85.371 -67.588 -55.257 -49.608
Goodwill, Net 1692.66 1827.61 958.303 920.018 927.63
Intangibles, Net 5794.44 7152.33 2195.05 2440.98 2731.33
Other Long Term Assets, Total 440.64 363.945 285.875 276.743 110.164
Total Current Liabilities 933.193 809.303 653.745 364.49 345.487
Accounts Payable 90.758 100.298 26.945 47.545 40.602
Accrued Expenses 802.874 647.479 349.107 266.836 263.427
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 31.381 31.406 246.322 33.387 33.387
Other Current Liabilities, Total 8.18 30.12 31.371 16.722 8.071
Total Liabilities 7749.52 8333.45 2876.16 2427.92 2446.07
Total Long Term Debt 5698.55 6025.21 1848.52 1573.87 1563.03
Long Term Debt 5693.34 6018.94 1848.52 1573.87 1563.03
Deferred Income Tax 944.337 1300.54 130.397 224.095 309.097
Other Liabilities, Total 173.44 198.392 243.498 265.461 228.46
Total Equity 3085.73 3965.19 3659.75 3110.98 2757.42
Common Stock 0.061 0.061 0.061 0.061 0.061
Additional Paid-In Capital 3477.12 3534.79 2633.67 2266.03 2113.63
Retained Earnings (Accumulated Deficit) 734.058 830.698 1160.37 1068.29 841.522
Other Equity, Total -1125.51 -400.36 -134.352 -223.393 -197.791
Total Liabilities & Shareholders’ Equity 10835.3 12298.6 6535.9 5538.9 5203.49
Total Common Shares Outstanding 63.214 61.633 56.171 56.14 57.504
Cash 334.018 510.747 517.117 333.172 215.606
Capital Lease Obligations 5.21 6.269
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 2784.65 2606.14 2571.5 2590.83 2500.86
Cash and Short Term Investments 1167.91 881.482 899.358 771.265 490.835
Cash 424.139 334.018 296.686 380.328 410.125
Cash & Equivalents 563.772 517.464 542.672 290.937
Short Term Investments 180 30 60 100 80.71
Total Receivables, Net 681.154 651.493 601.179 594.034 572.392
Accounts Receivable - Trade, Net 623.938 651.493 601.179 594.034 572.392
Total Inventory 674.778 714.061 728.074 861.705 985.454
Prepaid Expenses 72.779 91.912 92.877 108.304 117.399
Other Current Assets, Total 188.028 267.192 250.016 255.525 334.776
Total Assets 11047.1 10835.3 10384.7 11200.1 11768.9
Property/Plant/Equipment, Total - Net 303.09 301.376 290.067 317.888 341.044
Property/Plant/Equipment, Total - Gross 419.23 409.023 388.038 414.57 433.74
Accumulated Depreciation, Total -116.14 -107.647 -97.971 -96.682 -92.696
Goodwill, Net 1723.44 1692.66 1592.64 1687.65 1782.44
Intangibles, Net 5764.21 5794.44 5570.39 6237.96 6783.06
Other Long Term Assets, Total 471.732 440.64 360.067 365.805 361.516
Total Current Liabilities 908.902 933.193 812.954 705.442 737.409
Accounts Payable 125.454 90.758 102.249 74.161 73.336
Accrued Expenses 711.779 803.255 630.648 569.174 596.292
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 31 31 31 31 31
Other Current Liabilities, Total 40.669 8.18 49.057 31.107 36.781
Total Liabilities 7712.08 7749.52 7639.47 7999.35 8160.43
Total Long Term Debt 5689.66 5693.34 5695.81 5990 5992.87
Long Term Debt 5689.66 5693.34 5695.81 5990 5992.87
Deferred Income Tax 932.247 944.337 933.67 1096.42 1222.08
Other Liabilities, Total 181.273 178.65 197.035 207.496 208.069
Total Equity 3335.04 3085.73 2745.19 3200.78 3608.49
Common Stock 0.061 0.061 0.061 0.061 0.061
Additional Paid-In Capital 3511.73 3477.12 3388 3312.32 3239.33
Retained Earnings (Accumulated Deficit) 803.478 734.058 974.782 994.43 959.819
Other Equity, Total -980.23 -1125.51 -1617.65 -1106.03 -590.72
Total Liabilities & Shareholders’ Equity 11047.1 10835.3 10384.7 11200.1 11768.9
Total Common Shares Outstanding 63.987 63.214 62.89 62.623 62.244
Capital Lease Obligations
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -224.06 -329.668 238.616 523.367 447.098
Cash From Operating Activities 1271.98 778.507 899.648 776.401 798.904
Cash From Operating Activities 30.302 26.714 18.673 15.342 15.233
Amortization 599.169 525.769 259.58 354.814 201.498
Deferred Taxes -292.251 69.198 -136.937 -236.61 -88.815
Non-Cash Items 875.52 311.361 605.153 269.572 200.604
Cash Taxes Paid 94.681 271.217 226.823 183.61 164.217
Cash Interest Paid 270.671 138.271 42.47 43.002 42.706
Changes in Working Capital 283.297 175.133 -85.437 -150.084 23.286
Cash From Investing Activities -446.23 -5212.14 -1007.67 -155.3 -394.487
Capital Expenditures -498.194 -45.532 -379.254 -182.335 -131.47
Other Investing Cash Flow Items, Total 51.964 -5166.61 -628.416 27.035 -263.017
Cash From Financing Activities -529.491 3970.52 528.073 -293.745 -479.13
Financing Cash Flow Items -45.443 -35.602 -16.877 -16.739 -23.078
Issuance (Retirement) of Stock, Net 97.966 135.261 -46.856 -243.619 -430.335
Issuance (Retirement) of Debt, Net -582.014 3870.86 591.806 -33.387 -25.717
Foreign Exchange Effects -6.222 -3.207 0.374 0.366 -1.7
Net Change in Cash 290.034 -466.321 420.425 327.722 -76.413
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 69.42 -224.06 16.664 36.312 1.647
Cash From Operating Activities 320.708 1271.98 930.006 512.015 208.979
Cash From Operating Activities 7.574 30.302 22.958 15.364 7.617
Amortization 149.786 599.169 461.782 320.55 172.094
Deferred Taxes -66.061 -292.251 -146.874 -82.315 -45.339
Non-Cash Items 81.207 875.52 421.208 208.514 49.707
Changes in Working Capital 78.782 283.297 154.268 13.59 23.253
Cash From Investing Activities -4.822 -446.23 -121.852 -126.454 -37.292
Capital Expenditures -4.822 -498.194 -113.816 -118.718 -37.292
Other Investing Cash Flow Items, Total 51.964 -8.036 -7.736 0
Cash From Financing Activities -29.788 -529.491 -549.087 -260.034 -270.811
Financing Cash Flow Items -43.266 -45.443 -42.632 -40.065 -33.776
Issuance (Retirement) of Stock, Net 21.228 97.966 67.809 46.549 21.729
Issuance (Retirement) of Debt, Net -7.75 -582.014 -574.264 -266.518 -258.764
Foreign Exchange Effects 0.331 -6.222 -11.157 -5.71 -1.489
Net Change in Cash 286.429 290.034 247.91 119.817 -100.613
Cash Taxes Paid 94.681
Cash Interest Paid 270.671
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.0037 6315834 173293 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 8.7097 5498852 130439 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.7577 2372395 42703 2023-06-30 LOW
LSV Asset Management Investment Advisor 3.6692 2316547 -1856 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.9581 1867582 11642 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 2.554 1612482 -297493 2023-06-30 LOW
Samlyn Capital, LLC Hedge Fund 2.1323 1346230 557605 2023-06-30 HIGH
Polaris Capital Management, LLC Investment Advisor 2.0538 1296660 -11200 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 2.0434 1290109 35500 2023-06-30 HIGH
Deep Track Capital LP Hedge Fund 1.9799 1250000 50000 2023-06-30 HIGH
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.9559 1234872 66367 2023-06-30 LOW
Mulligan (Seamus C) Individual Investor 1.8529 1169814 3075 2023-08-11 LOW
Franklin Advisers, Inc. Investment Advisor/Hedge Fund 1.7308 1092730 -192632 2023-06-30 LOW
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund 1.7239 1088389 18395 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.6451 1038652 129999 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5809 998067 44286 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.3019 821923 -18080 2023-06-30 LOW
Avidity Partners Management LP Hedge Fund 1.1131 702778 24878 2023-06-30 HIGH
Pacer Advisors, Inc. Investment Advisor 1.0839 684289 206243 2023-06-30 HIGH
The Baupost Group, L.L.C. Investment Advisor/Hedge Fund 1.0671 673696 195000 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Jazz Pharma Company profile

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.

Equity composition

Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.

Industry: Pharmaceuticals (NEC)

Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

ETH/USD

1,590.41 Price
-0.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

US100

14,686.10 Price
-0.120% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.51 Price
-0.380% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Oil - Crude

89.36 Price
-0.810% 1D Chg, %
Long position overnight fee 0.0538%
Short position overnight fee -0.0757%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading